New Clinical Trial Data Demonstrates BD Libertas Wearable Injector As A Drug Delivery System
BD (Becton, Dickinson and Company), a leading global medical technology company, today announced publication of the results from a 52-subject human clinical trial with the BD Libertas Wearable Injector. The subcutaneous drug delivery system, currently in final phases of development, is designed as ready to use and to deliver drugs such as biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations.
This research to evaluate the performance of the 5 mL BD Libertas device in human subjects, including tissue effects, skin reactivity and patient acceptance, confirms that the BD Libertas device delivered within an acceptable time period 5 mL of 8 cP injections to the abdomen and thigh regardless of subject age, gender, or BMI and with/without patient movement.